FNTA
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha
As of the edition of 20 October 2026, FNTA (protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha, UniProt P49354) has 2 drugs tested at it and 7 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P49354
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 14
- Disease areas
- Cancer; Blood and lymph; Inherited and neonatal; Skin and connective tissue; Digestive system; Immune system; Nervous system; Lungs and airways
- Registered trials of its drugs
- 123
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tipifarnib | Stopped | Phase 3 | none listed |
| Lonafarnib | Marketed | Phase 3 | Ends 2027 |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 7 |
| Total on the list | 7 |